Skip to main content
SpringerLink
Log in

Prognostic histological and immune markers of renal cell carcinoma

  • Article
  • Published:
Pathology Oncology Research

Abstract

Recent development on the fields of molecular genetics and immunology of human renal cell carcinoma (RCC) have resulted in more successful treatment of advanced and metastatic RCCs. Re-evaluation of the prognostic/predictive data aim the initial tumor staging of RCC patients to achieve better patient selection for immune and gene therapy. 125 RCC patients diagnosed according to the Heidelberg histological classification, graded, Robson staged, immune treated (Interferon-α + Vinblastin or Broncho-Waxom/Decaris) were followed-up clinically for 36 months. Tumor immunity markers by immunohistochemistry of tumor infiltrating lymphocytes (TIL) were detected by immunoperoxidase methods using monoclonal antibodies. Tumoral immune complexes (TIC) were visualized by fluorescent polyclonal antibodies. Histologically oncocytomas defined a better (p<0.02) and sarcomatous RCCs a worse (p<0.01) follow-up prognosis. Basically, the metastatic status (related with the stage and grade) determined the clinical outcome (p<0.00002) of the RCC patients. Tumoral immune complexes (TIC) were weak positive, while tumor infiltrating lymphocytes (TIL) weak negative predictors of the succes of Broncho-Waxom/Decaris immune therapy. Molecular genetic based histological classification, grade, stage and metastatic status parameters together with some tumor immunity parameters (TIL, TIC) can predict the success of immunotherapy of RCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

RCC:

renal cell carcinoma

onc:

oncocytic

chr:

chromophobe

pap:

papillary

mixed:

mixed type

NP:

non-papillary; sarcomatous

met:

metastasis

std:

stage

grd:

grade

VHL:

von Hippel Lindau gene

TIL:

tumor infiltrating lymphocytes

TIC:

tumoral immune complexes

IL-2:

interleukin-2

LAK:

lymphokine activated killer cells

IFN-γ:

interferon-γ

NK-cells:

natural killer cells

MHC:

major histocompatibility complex

IFN-α + VINBL therapy:

Interferon-α2b (Intron-A) + Vinblastin treatment

B/D-therapy:

BronchoWaxom/Decaris treatment

PD:

progressive disease

SD:

stable disease

PR:

partial response

CR:

complete response

References

  1. Angevin E, Kreme, F, Gaudin C, et al: Analysis of T-cell immune response in renal cell carcinoma: polarisation to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 72:431–440, 1997.

    Article  PubMed  CAS  Google Scholar 

  2. Belldegrun A, Tao CL, Kaboo R, et al: Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interluekin-2-based therapy. J Immunother Tumor Immunol 19:149–161, 1996.

    CAS  Google Scholar 

  3. Bezooijen van RL, Goey H, Stoter G, et al: Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2. Cancer Immunol Immunother 43:293–298, 1996.

    Article  PubMed  Google Scholar 

  4. Brouwenstijn N, Gaugler B, Kruse KM, et al: Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor infiltrating lymphocytes. Int J Cancer 68:177–182, 1996.

    Article  PubMed  CAS  Google Scholar 

  5. Buszello H, Ackermann R: Immunohistochemical studies on the expression of HLA Class I antigen in renal cell carcinoma: comparison of primary and metastatic tumor tissue. Eur Urol 25:158–163, 1994.

    PubMed  CAS  Google Scholar 

  6. Buzogány I, Czvalinga I, Götz F: Ambulanter végzett interferon monoés kombinációs terápia eredménye elôrehaladott vesedaganat esetén. Orv Hetil 138:67–70, 1997.

    PubMed  Google Scholar 

  7. Chang AE, Aruga A, Cameron MJ, et al: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15:796–807, 1997.

    PubMed  CAS  Google Scholar 

  8. Corless CL, Kibel AS, Iliopoulos O, et al: Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 28:459–463, 1996.

    Article  Google Scholar 

  9. Crotty TB, Farrow GM, Liber HJ: Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol 154:964–967, 1996.

    Article  Google Scholar 

  10. Curnow RT: Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunther 45:210–215, 1997.

    Article  CAS  Google Scholar 

  11. Hove van den LE, van Gool SW, van Poppel, et al: Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumor-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 109:501–509, 1997.

    Article  PubMed  Google Scholar 

  12. Hove van den LE, van Gool SW, van Poppel, et al: Identification of an enriched CD4+ CD8alpha++ CD8beta+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. Int J Cancer 71:178–182, 1997.

    Article  PubMed  Google Scholar 

  13. Jantzer P, Schendel DJ: Human renal cell carcinoma antigenspecific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 58:3078–3086, 1998.

    PubMed  CAS  Google Scholar 

  14. Kawata N, Akimoto Y, Hirano D, et al: Immunological effect of recombinant interferon-gamma on tumor infiltrating lymphocytes of renal cell carcinoma - relationshship with clinical stage (Japanese). Hinyokika-Kiyo 42:1–4, 1996.

    PubMed  CAS  Google Scholar 

  15. Knebelman B, Ananth S, Cohen HT, et al: Transforming growth factoc alpha is a target fro the von Hippel-Lindau tumor suppressor. Cancer Res 58:226–231, 1998.

    Google Scholar 

  16. Kovacs Gy, Akhtar M, Beckwith BJ, et al: The Heidelberg classification of renal cell tumors. J Pathol 183:131–133, 1997.

    Article  PubMed  CAS  Google Scholar 

  17. Kovacs Gy, Erlandsson R, Boldog F, et al: Consistent chromosome 3p deletion and loss of heterozygositiy in renal cell carcinoma. Proc Natl Acad Sci USA 85:1571–1575, 1988.

    Article  PubMed  CAS  Google Scholar 

  18. Kowalczyk D, Skorupski W Kwias Z, et al: Flow cytometric analysis of tumor-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 80:543–547, 1997.

    PubMed  CAS  Google Scholar 

  19. Krumm A, Groudine M: Tumor suppression and transciption elongation: the dier consequences of changing partners. Science 269:1400–1401, 1995.

    Article  PubMed  CAS  Google Scholar 

  20. Licht MR, Novick AC, Tubbs RR, et al: Renal oncocytoma: clinical and biological correlates. J Urol 150:1380–1383, 1993.

    PubMed  CAS  Google Scholar 

  21. Lubensky IA, Schmidt L, Zhuang Z, et al: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155:517–526, 1999.

    PubMed  CAS  Google Scholar 

  22. Magyarlaki T, Kiss B, Buzogány I, et al: Renal cell carcinoma and paraneoplastic IgA nephropathy. Nephron 82:127–130, 1999.

    Article  PubMed  CAS  Google Scholar 

  23. Magyarlaki T, Mosolits S, Baranyay F, et al: Immunohistochemistry of complement responses on human renal cell carcinoma biopsies. Tumori 82:473–480, 1996.

    PubMed  CAS  Google Scholar 

  24. Moch H, Schraml P, Bubendorf L, et al: Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal carcinoma detected by fluorescence in situ hybridization. Cancer Res 58:2304–2309, 1998.

    PubMed  CAS  Google Scholar 

  25. Neumann HPH, Bender BU, Berger DP, et al: Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic reanl cell carcinoma. J Urol 160:1248–1254, 1998.

    Article  PubMed  CAS  Google Scholar 

  26. Olive C, Nikol D, Falk MC: Characterisation of gamma delta T cells in renal cell carcinoma patinets by polymerase chain reaction analysis of T cell receptor transcripts. Cancer Immunol Immunother 44:27–34, 1997.

    Article  PubMed  CAS  Google Scholar 

  27. Siemeister G, Weindel K, Mohrs K, et al: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau suppressor protein. Cancer Res 56:2299–2301, 1996.

    PubMed  CAS  Google Scholar 

  28. Surfus JE, Hank JA, Oosterwijk E, et al: Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother Tumor Immunol 19:184–191, 1996.

    CAS  Google Scholar 

  29. Toliou T, Stravoravd P Polyzonis M, et al: Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohistochemical study. Eur Urol 29:252–256, 1996.

    PubMed  CAS  Google Scholar 

  30. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 352:1691–1696, 1998.

    Article  PubMed  CAS  Google Scholar 

  31. Weijtens ME, Willemsen RA, van Krimpen BA, et al: Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 77:181–187, 1998.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, 2nd Department of Medicine, University of Pécs, Medical Faculty, Pécs, Hungary

    Tamás Magyarlaki, Róbert Döbrönte & Barbara Simon

  2. Department of Urology, 2nd Department of Medicine, University of Pécs, Medical Faculty, Pécs, Hungary

    István Buzogány

  3. Department of Pathology, 2nd Department of Medicine, University of Pécs, Medical Faculty, Pécs, Hungary

    László Kaiser & Farkas Sükösd

  4. Nephrology Center, 2nd Department of Medicine, University of Pécs, Medical Faculty, Pécs, Hungary

    Attila Fazekas & Judit Nagy

Authors
  1. Tamás Magyarlaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. István Buzogány
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. László Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farkas Sükösd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Róbert Döbrönte
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Attila Fazekas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Judit Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tamás Magyarlaki.

Additional information

This work was supported by the grants of the Hungarian Academy of Sciences (BOLYAI-BO00049/99 and OTKA-T0220986)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magyarlaki, T., Buzogány, I., Kaiser, L. et al. Prognostic histological and immune markers of renal cell carcinoma. Pathol. Oncol. Res. 7, 118–124 (2001). https://doi.org/10.1007/BF03032577

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03032577

Keywords

Search

Navigation